Related references
Note: Only part of the references are listed.Risk of hospitalised infection in rheumatoid arthritis patients receiving biologics following a previous infection while on treatment with anti-TNF therapy
Huifeng Yun et al.
ANNALS OF THE RHEUMATIC DISEASES (2015)
Risk of Hospitalized Bacterial Infections Associated With Biologic Treatment Among US Veterans With Rheumatoid Arthritis
J. R. Curtis et al.
ARTHRITIS CARE & RESEARCH (2014)
Risk of skin and soft tissue infections (including shingles) in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register
James B. Galloway et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
Difference in the risk of serious infections in patients with rheumatoid arthritis treated with adalimumab, infliximab and etanercept: results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry
Sanne A. A. van Dartel et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
Risk of infections in rheumatoid arthritis patients switching from anti-TNF agents to rituximab, abatacept, or another anti-TNF agent, a retrospective administrative claims analysis
Stephen S. Johnston et al.
SEMINARS IN ARTHRITIS AND RHEUMATISM (2013)
Lack of adverse effect of anti-tumor necrosis factor-a biologics in treatment of rheumatoid arthritis: 5 years follow-up
Ahmed M. Dewedar et al.
INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES (2012)
Role of disease risk scores in comparative effectiveness research with emerging therapies
Robert J. Glynn et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2012)
Overview of safety of non-biologic and biologic DMARDs
Eric M. Ruderman
RHEUMATOLOGY (2012)
Use of a disease risk score to compare serious infections associated with anti-tumor necrosis factor therapy among high- versus lower-risk rheumatoid arthritis patients
Jeffrey R. Curtis et al.
ARTHRITIS CARE & RESEARCH (2012)
The comparative risk of serious infections among rheumatoid arthritis patients starting or switching biological agents
Jeffrey R. Curtis et al.
ANNALS OF THE RHEUMATIC DISEASES (2011)
Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient?
A. Strangfeld et al.
ANNALS OF THE RHEUMATIC DISEASES (2011)
Use of Biologics in Rheumatoid Arthritis: Current and Emerging Paradigms of Care
Jeffrey R. Curtis et al.
CLINICAL THERAPEUTICS (2011)
Initiation of Tumor Necrosis Factor-α Antagonists and the Risk of Hospitalization for Infection in Patients With Autoimmune Diseases
Carlos G. Grijalva et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2011)
Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR)
W. G. Dixon et al.
ANNALS OF THE RHEUMATIC DISEASES (2010)
The Risk of Infections with Biologic Therapies for Rheumatoid Arthritis
Daniel E. Furst
SEMINARS IN ARTHRITIS AND RHEUMATISM (2010)
Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study
R. Fleischmann et al.
ANNALS OF THE RHEUMATIC DISEASES (2009)
A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: a Cochrane overview
Jasvinder A. Singh et al.
CANADIAN MEDICAL ASSOCIATION JOURNAL (2009)
Administrative codes combined with medical records based criteria accurately identified bacterial infections among rheumatoid arthritis patients
Nivedita M. Patkar et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2009)
Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate
Jonathan Kay et al.
ARTHRITIS AND RHEUMATISM (2008)
The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies
Erik von Elm et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2008)
Serious infection following anti-tumor necrosis factor α therapy in patients with rheumatoid arthritis -: Lessons from interpreting data from observational studies
W. G. Dixon et al.
ARTHRITIS AND RHEUMATISM (2007)
Anti-tumor necrosis factor a therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis
Sebastian Schneeweiss et al.
ARTHRITIS AND RHEUMATISM (2007)
Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor α antagonists
Jeffrey R. Curtis et al.
ARTHRITIS AND RHEUMATISM (2007)
Confirmation of administrative claims-identified opportunistic infections and other serious potential adverse events associated with tumor necrosis factor α antagonists and disease-modifying antirheumatic drugs
J. R. Curtis et al.
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH (2007)
Efficacy and safety of combination etanercept and methotrexate versus etanercept alone in patients with rheumatoid arthritis with an inadequate response to methotrexate: the ADORE study
P. L. C. M. van Riel et al.
ANNALS OF THE RHEUMATIC DISEASES (2006)
Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy - Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks
Stanley B. Cohen et al.
ARTHRITIS AND RHEUMATISM (2006)
Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs - A one-year randomized, placebo-controlled study
M. Weinblatt et al.
ARTHRITIS AND RHEUMATISM (2006)
Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate
R. N. Maini et al.
ARTHRITIS AND RHEUMATISM (2006)
Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy - Results from the British Society for Rheumatology Biologics Register
W. G. Dixon et al.
ARTHRITIS AND RHEUMATISM (2006)
Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis - A randomized trial
Joel M. Kremer et al.
ANNALS OF INTERNAL MEDICINE (2006)
Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies - Systematic review and meta-analysis of rare harmful effects in randomized controlled trials
T Bongartz et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment - Results of a phase IIb randomized, double-blind, placebo-controlled, dose-ranging trial
P Emery et al.
ARTHRITIS AND RHEUMATISM (2006)
Infections in patients with rheumatoid arthritis treated with biologic agents
J Listing et al.
ARTHRITIS AND RHEUMATISM (2005)
Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy - A randomized, placebo-controlled, 52-week trial
EC Keystone et al.
ARTHRITIS AND RHEUMATISM (2004)
Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate
RN Maini et al.
ARTHRITIS AND RHEUMATISM (2004)
Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial
L Klareskog et al.
LANCET (2004)
Combination of infliximab and methotrexate therapy for early rheumatoid arthritis - A randomized, controlled trial
EWS Clair et al.
ARTHRITIS AND RHEUMATISM (2004)
Adalimumab, a fully human anti-tumor necrosis factor a monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate - The ARMADA trial
ME Weinblatt et al.
ARTHRITIS AND RHEUMATISM (2003)
Predictors of infection in rheumatoid arthritis
MF Doran et al.
ARTHRITIS AND RHEUMATISM (2002)
Share Paper
